Tradestie Institutional Equity Comparison Engine

AVDL vs GBIO โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-02-11 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

AVDL Overall Edge

AVDL Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avadel Pharmaceuticals plc Ordinary Share (AVDL) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while GBIO counters with relative strength in Valuation. Fundamentally, AVDL trades at 28.8x Forward P/E with 2.5% operating margin (+54.9% YoY revenue) versus GBIO at 7.9x Forward P/E and -2020.0% operating margin (-78.9% YoY). In options structure, AVDL sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against GBIO sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner GBIO
AVDL 28.8x vs GBIO 7.9x Fwd P/E
Growth & Margin Winner AVDL
Op Margin 2.5% vs -2020.0% ยท YoY +54.9% vs -78.9%
Momentum & Technical Winner AVDL
1Y +138.1% vs -35.8% ยท 52W Pos 89% vs 62%
Options & Structure Winner AVDL
UNCLASSIFIED (<1st %ile IV) vs UNCLASSIFIED (N/A IV)
AVDL NASDAQ
Avadel Pharmaceuticals plc Ordinary Share
Pharmaceutical Preparations
$21.64
+0.05% 1D
Market Cap $2.1B
1M Return +0.65%
1Y Return +138.06%
Forward P/E 28.8x
Unified AI Score
62.9 / 100 BUY
Tech 75.0 Fund 60.0 Flow 50.0 Mom 50.0
GBIO NASDAQ
Generation Bio Co. Common Stock
Pharmaceutical Preparations
$5.34
-6.97% 1D
Market Cap $38.7M
1M Return -2.38%
1Y Return -35.83%
Forward P/E 7.9x
Unified AI Score
58.8 / 100 HOLD
Tech 40.0 Fund 47.0 Flow 50.0 Mom 53.9

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: AVDL +138.06% GBIO -35.83% Spread: +162.32 pp (AVDL Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
AVDL TTM Op. Margin: 2.5% GBIO TTM Op. Margin: -2020.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AVDL vs GBIO. Trailing 12-month operating profitability (AVDL 2.5% vs GBIO -2020.0%) and valuation multiples (AVDL 28.8x vs GBIO 7.9x Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: AVDL (7) vs GBIO (2)
Institutional Metric AVDL GBIO Criterion Row Winner
Market Capitalization Scale $2.1B $38.7M Larger Scale AVDL
Trailing P/E Ratio Valuation 16.8x 7.9x Lower Multiple GBIO
Forward P/E Ratio Valuation 28.8x 7.9x Lower Multiple GBIO
Revenue Growth (YoY) Growth +54.9% -78.9% Higher Growth AVDL
Operating Margin (TTM) Profitability 2.5% -2020.0% Higher Margin AVDL
Net Profit Margin Profitability -0.1% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -0.3% -80.8% Higher ROE AVDL
52-Week Range Position Momentum 89% ($6โ€“$24) 62% ($0โ€“$8) Stronger Trend AVDL
Beta / 30D Volatility Risk Regime 0.14ฮฒ ยท 2% Vol 0.80ฮฒ ยท 26% Vol Lower Realized Risk AVDL
Unified Institutional Score Composite Signal 62.9 / 100 (BUY) 58.8 / 100 (HOLD) Higher Composite AVDL

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full AVDL vs GBIO Buy Guide
AVDL UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live AVDL Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
GBIO UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live GBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither AVDL nor GBIO registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.